Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy

Thrombosis Research

Volumn 136, Issue 3, 2015, Pages 673-681

  Jacobsen, Christine ^a   Oechsle, Karin ^a   Hauschild, Jessica ^a   Steinemann, Gustav ^a   Spath, Brigitte ^a   Bokemeyer, Carsten ^a   Ruf, Wolfram ^b,c   Honecker, Friedemann ^a,d   Langer, Florian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Tumor Center ZeTuP   (Switzerland)

Author keywords

Cancer; Chemotherapy; Phosphatidylserine; Thrombosis; Tissue factor

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOFOS; MESSENGER RNA; PHOSPHATIDYLSERINE; PROCOAGULANT; RECOMBINANT THROMBOPLASTIN; ANTINEOPLASTIC AGENT; THROMBOPLASTIN;

APOPTOSIS; ARTICLE; BLOOD CLOTTING TEST; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE ASSAY; CELL SURFACE; CONTROLLED STUDY; EMBRYO; EMBRYONAL CARCINOMA CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GERM CELL TUMOR; HUMAN; HUMAN CELL; MALE; NON SEMINOMATOUS GERMINOMA; NT2 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STAGE CLOTTING ASSAY; TCAM 2 CELL LINE; THROMBIN TIME; WESTERN BLOTTING; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HL 60 CELL LINE; METABOLISM; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; THROMBOPLASTIN;

EID: 84940440797     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.07.002     Document Type: Article

References (23)

1. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, E.P. Balaban, J.M. Clarke, C.R. Flowers, C.W. Francis, L.E. Gates, A.K. Kakkar, N.S. Key, M.N. Levine, H.A. Liebman, M.A. Tempero, S.L. Wong, A.A. Prestrud, A. Falanga, and American Society of Clinical Oncology Clinical Practice Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J. Clin. Oncol. 31 2013 2189 2204
2. N.I. Weijl, M.F. Rutten, A.H. Zwinderman, H.J. Keizer, M.A. Nooy, F.R. Rosendaal, F.J. Cleton, and S. Osanto Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature J. Clin. Oncol. 18 10 2000 2169 2178
3. T. Proverbs-Singh, S.K. Chiu, Z. Liu, S. Seng, G. Sonpavde, T.K. Choueiri, C.K. Tsao, M. Yu, N.M. Hahn, W.K. Oh, and M.D. Galsky Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis J. Natl. Cancer Inst. 104 23 2012 1837 1840
4. S. Seng, Z. Liu, S.K. Chiu, T. Proverbs-Singh, G. Sonpavde, T.K. Choueiri, C.K. Tsao, M. Yu, N.M. Hahn, W.K. Oh, and M.D. Galsky Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis J. Clin. Oncol. 30 35 2012 4416 4426
5. F. Honecker, D. Koychev, A.D. Luhmann, F. Langer, K.P. Dieckmann, C. Bokemeyer, and K. Oechsle Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy Onkologie 36 11 2013 663 668
6. D. Lechner, M. Kollars, A. Gleiss, P.A. Kyrle, and A. Weltermann Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity J. Thromb. Haemost. 5 12 2007 2445 2452
7. K.P. Dieckmann, W.J. Struss, and U. Budde Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour Anticancer Res. 31 12 2011 4501 4505
8. Z. Lysov, L.L. Swystun, S. Kuruvilla, A. Arnold, and P.C. Liaw Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption Blood Coagul. Fibrinolysis 26 1 2015 36 45
9. J. Walsh, H.R. Wheeler, and C.L. Geczy Modulation of tissue factor on human monocytes by cisplatin and adriamycin Br. J. Haematol. 81 4 1992 480 488
10. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 10 2008 4902 4907
11. A.E. Fenske, S. Glaesener, C. Bokemeyer, J. Thomale, J. Dahm-Daphi, F. Honecker, and D.C. Dartsch Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair Cancer Lett. 324 2 2012 171 178
12. F. Langer, B. Spath, C. Fischer, M. Stolz, F.A. Ayuk, N. Kröger, C. Bokemeyer, and W. Ruf Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase Blood 121 12 2013 2324 2335
13. J. Ahamed, M. Belting, and W. Ruf Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1 Blood 105 6 2005 2384 2391
14. K. Oechsle, F. Honecker, T. Cheng, F. Mayer, P. Czaykowski, E. Winquist, L. Wood, M. Fenner, S. Glaesener, J.T. Hartmann, K. Chi, C. Bokemeyer, and C. Kollmannsberger Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study Ann. Oncol. 22 12 2011 2654 2660
15. Q. Wang, K. Cui, O. Espin-Garcia, D. Cheng, X. Qiu, Z. Chen, M. Moore, R.G. Bristow, W. Xu, S. Der, and G. Liu Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis PLoS One 8 12 2013 e82363
16. F. Wei, D. Ojo, X. Lin, N. Wong, L. He, J. Yan, S. Xu, P. Major, and D. Tang BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation Oncogene 34 23 2015 3063 3075
17. F. Langer, and C. Bokemeyer Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor Hamostaseologie 32 2 2012 95 104
18. L.G. van den Hengel, A.Q. van Steijn-van Tol, R.M. Bertina, H.H. Versteeg, and S. Osanto Microparticle-associated tissue factor activity in plasma is unaffected by cytolytic chemotherapy treatment in metastatic testicular cancer patients Thromb. Res. 131 2 2013 187 189
19. F. Langer, A. Amirkhosravi, S. Loges, T. Meyer, B. Eifrig, D.K. Hossfeld, W. Fiedler, and J.L. Francis An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF Thromb. Haemost. 92 5 2004 1136 1146
20. J.C. Boles, J.C. Williams, R.M. Hollingsworth, J.G. Wang, S.L. Glover, A.P. Owens III, D.A. Barcel, R.S. Kasthuri, N.S. Key, and N. Mackman Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity Thromb. Res. 129 2 2012 197 203
21. R.R. Bach Tissue factor encryption Arterioscler. Thromb. Vasc. Biol. 26 3 2006 456 461
22. F. Langer, and W. Ruf Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation Thromb. Haemost. 111 4 2014 590 597
23. M.C. Martinez, S. Tual-Chalot, D. Leonetti, and R. Andriantsitohaina Microparticles: targets and tools in cardiovascular disease Trends Pharmacol. Sci. 32 11 2011 659 665